Joakim Oxelbark
Oerebro, T, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit.
Journal: The Journal of antimicrobial chemotherapy
Published: June 22, 2025
LC-MS/MS analysis of 11-nor-9-carboxy-hexahydrocannabinol (HHC-COOH) and 11-hydroxy-hexahydrocannabinol (HHC-OH) for verification of hexahydrocannabinol (HHC) intake.
Journal: Scandinavian journal of clinical and laboratory investigation
Published: March 26, 2024
Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea.
Journal: The Journal of antimicrobial chemotherapy
Published: January 15, 2024
Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model.
Journal: Frontiers in pharmacology
Published: September 10, 2023
Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections.
Journal: Frontiers in pharmacology
Published: September 03, 2022
Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.
Journal: Frontiers in pharmacology
Published: February 14, 2022
Ultrafast LC-MS/MS analysis of 5-hydroxyindoleacetic acid (5-HIAA) in serum.
Journal: Scandinavian journal of clinical and laboratory investigation
Published: June 08, 2021
Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.
Journal: Frontiers in pharmacology
Published: March 17, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026